Drug Name:
PRED MILD Rx
Generic Name and Formulations:
Prednisolone acetate 0.12%; oph. susp; contains benzalkonium chloride, sulfites.
Company:
Allergan
Therapeutic Use:
Indications for PRED MILD:
Ocular inflammation.
Adults and Children:
Instill 1–2 drops 2–4 times daily. During the initial 24–48hrs, the dosing frequency may be increased if needed.
Contraindications:
Fungal, mycobacterial, viral (except herpes zoster) or untreated bacterial infections.
Warnings/Precautions:
Corneal or scleral thinning. Glaucoma. Myopia. Diabetes. Asthma. Monitor for secondary infections and intraocular pressure in prolonged use. May mask or exacerbate infections. Avoid abrupt cessation. Re-evaluate if no improvement after 2 days. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Steroid.
Adverse Reactions:
Increased intraocular pressure, posterior subcapsular cataract formation, delayed wound healing, corneal perforations, optic nerve damage, defects in visual acuity and fields of vision, allergic reactions, dysgeusia, eye pain, foreign body sensation, headache, others.
How Supplied:
Mild—5mL, 10mL; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |